More than 300 biotech executives and investors have signed a letter urging President Trump to replace departed FDA Commissioner Marty Makary with former agency official Richard Pazdur.
Why it matters: Predictable drug approval decisions and stable regulatory leadership are vital to biopharma bottom lines.
